Pharmacotherapy For Depression And Treatment Resistant Depression
Download Pharmacotherapy For Depression And Treatment Resistant Depression full books in PDF, epub, and Kindle. Read online free Pharmacotherapy For Depression And Treatment Resistant Depression ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : George I Papakostas |
| Publisher | : World Scientific |
| Total Pages | : 726 |
| Release | : 2010-04-28 |
| Genre | : Medical |
| ISBN | : 9814466670 |
This unique ground-breaking work, authored by renowned Harvard-based researchers G I Papakostas and M Fava, represents, by far, the most comprehensive compilation to date of medical studies and reports involving the use of antidepressants for the treatment of major depressive disorder, one of the most prevalent and devastating medical illnesses afflicting mankind today. Given the breadth of the scientific literature focusing on the use of antidepressants for major depressive disorder, this work represents an invaluable tool for clinicians as well as scientists in search of a reference manual to help guide them through the field. The book is organized into four parts; each part focusing on a separate theme that will facilitate the reader to precisely access particular information of interest, whether be it clinical or scientific in nature. Each part is then sub-divided into several thematic chapters, which are enriched with tables and figures citing results from the most influential studies in the field. Finally, clinical and research “pearls” are listed throughout the book in bullet-point fashion to help summarize the available knowledge-base in a user-friendly format.
| Author | : Joseph Zohar |
| Publisher | : |
| Total Pages | : 456 |
| Release | : 1987 |
| Genre | : Religion |
| ISBN | : |
| Author | : Gustavo H. Vazquez |
| Publisher | : Academic Press |
| Total Pages | : 170 |
| Release | : 2020-09-16 |
| Genre | : Medical |
| ISBN | : 0128210346 |
Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. - Provides efficacy research on ketamine as a treatment for depression - Identifies best practices for clinical use, both long-term and acute - Discusses the molecular mechanisms and neurobiology of action
| Author | : Sanjay J. Mathew |
| Publisher | : Springer |
| Total Pages | : 167 |
| Release | : 2016-11-25 |
| Genre | : Medical |
| ISBN | : 3319429256 |
This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.
| Author | : Joao Luciano de Quevedo |
| Publisher | : Elsevier |
| Total Pages | : 612 |
| Release | : 2022-04-04 |
| Genre | : Medical |
| ISBN | : 0128240679 |
Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD. Defines Treatment-Resistant Depression and Staging Treatment Intensity Includes Treatment-Resistant Depression options for children, adolescents, geriatrics, during pregnancy, and during post-partum and menopause transitions Discusses the use of Ketamine and Esketamine for treatment-resistant depression
| Author | : Somnath Mookherjee |
| Publisher | : Springer Nature |
| Total Pages | : 347 |
| Release | : 2020-09-30 |
| Genre | : Education |
| ISBN | : 3030348148 |
This book provides teaching scripts for medical educators in internal medicine and coaches them in creating their own teaching scripts. Every year, thousands of attending internists are asked to train the next generation of physicians to master a growing body of knowledge. Formal teaching time has become increasingly limited due to rising clinical workload, medical documentation requirements, duty hour restrictions, and other time pressures. In addition, today’s physicians-in-training expect teaching sessions that deliver focused, evidence-based content that is integrated into clinical workflow. In keeping with both time pressures and trainee expectations, academic internists must be prepared to effectively and efficiently teach important diagnostic and management concepts. A teaching script is a methodical and structured plan that aids in effective teaching. The teaching scripts in this book anticipate learners’ misconceptions, highlight a limited number of teaching points, provide evidence to support the teaching points, use strategies to engage the learners, and provide a cognitive scaffold for teaching the topic that the teacher can refine over time. All divisions of internal medicine (e.g. cardiology, rheumatology, and gastroenterology) are covered and a section on undifferentiated symptom-based presentations (e.g. fatigue, fever, and unintentional weight loss) is included. This book provides well-constructed teaching scripts for commonly encountered clinical scenarios, is authored by experienced academic internists and allows the reader to either implement them directly or modify them for their own use. Each teaching script is designed to be taught in 10-15 minutes, but can be easily adjusted by the reader for longer or shorter talks. Teaching Scripts in Internal Medicine is an ideal tool for internal medicine attending physicians and trainees, as well as physician’s assistants, nurse practitioners, and all others who teach and learn internal medicine.
| Author | : Neera Ghaziuddin |
| Publisher | : Oxford University Press |
| Total Pages | : 311 |
| Release | : 2013-12 |
| Genre | : Medical |
| ISBN | : 0199937893 |
This is a pioneering book about the use of ECT in adolescents who are diagnosed with severe, disabling psychiatric disorders or fail conventional treatment. Included are a review of the literature, firsthand experience of the authors and case descriptions making it an invaluable guide to treatment.
| Author | : Domenic A. Ciraulo |
| Publisher | : Springer |
| Total Pages | : 372 |
| Release | : 2004 |
| Genre | : Medical |
| ISBN | : 9781588291394 |
Provides a concise guide for clinicians prescribing antidepressants by outlining the biological origins of depression and the neurobiological mechanisms of antidepressant therapy. Also covered is the pharmacologic management of major depression, bipolar depression, anxiety with depression, geriatric depression, depression in substance abuse, depression in schizophrenic patients, and the management of depression during pregnancy. Experimental and herbal drug therapies for depression are also discussed. This volume is unique for its broad range of topics discussed and its strong preliminary treatment of physiology and pathophysiology.
| Author | : |
| Publisher | : Academic Press |
| Total Pages | : 404 |
| Release | : 2020-06-29 |
| Genre | : Medical |
| ISBN | : 0128201908 |
The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series
| Author | : Graziano Pinna |
| Publisher | : |
| Total Pages | : 412 |
| Release | : 2015-04-01 |
| Genre | : |
| ISBN | : 9781634820769 |
Fluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure.
